Articles

Kendra Grubb | Surgical Director of Structural Heart and Valve Center and Associate Professor of Cardiovascular Surgery at the Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA

Even surgeons are not unanimous when offering such a solution: ligation of the saphenofemoral junction (SFJ), stripping of the varicose veins, and resection of the greater saphenous vein (GSV)

Percutaneous treatment of chronic total occlusion (CTO) is considered one of the most challenging procedures due to the high incidence of complications and the relatively low success rate compared with non-CTO percutaneous coronary interventions (PCI).

Cardiac cavernous haemangiomas are rare benign tumours more commonly seen in the right heart; this case demonstrated a LAA cavernous haemangioma, which was unusual.

Primary intracardiac tumours are very rare, with an incidence of 0.02% of which myxomas are the most common.1,2 Commonly affecting the mid-aged female population, myxomas are typically located within the atrium (93%) and rarely within the ventricular systems (6–8%).

Transcatheter valve embolisation and migration (TVEM) into the left ventricle (LV) is especially significant and requires conversion to an emergency surgical technique, with unusually high mortality reported.

This document aims to provide an overview of the clinical and regulatory challenges faced in the use of cannabinoid-based products in medicine, without becoming a comprehensive humanity review of the literature on the medical possibilities of cannabinoids.

This article discusses the results published in 2020 and early 2021 from key clinical trials of PARP inhibitors in patients with advanced ovarian cancer in terms of long-term efficacy and survival rates.